Pembrolizumab, the active compound in Keytruda, has become a cornerstone of precision oncology, enabling targeted cancer treatment through immune checkpoint inhibition. By blocking the PD-1 pathway, pembrolizumab enhances the body’s immune response against tumor cells, offering a more effective and less toxic alternative to conventional therapies. This innovation is a major factor driving...
Italiano 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Greek